Sanofi gets rights to Oxford BioMedica's TroVax; ended
Sanofi-Aventis has licensed exclusive worldwide rights from Oxford BioMedica PLC to develop and commercialize TroVax, a cancer immunotherapy in late-stage clinical trials.
- Gene Therapy, Cell Therapy
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com